CEO Executive AssistantStrategic alliances are one of the defining features of the biotech industry. Few biotechs have the full complement of capabilities, capital, and channels needed to develop and commercialize a drug independently. Partnerships with larger pharmaceutical companies, technology platforms, contract research organizations, academic institutions, and co-development collaborators are how most biotechs get from discovery to patient.
Managing these alliances is one of the most demanding dimensions of the biotech CEO role. The stakes are high: a poorly managed alliance can delay development timelines, trigger opt-out clauses, or poison relationships that took years to build. But the operational dimensions of alliance management are also highly delegable, and biotech CEOs who remain too operationally involved in alliance management are using scarce leadership time on work that experienced alliance managers can handle.
This guide gives biotech CEOs a practical framework for delegating alliance management while maintaining the strategic partner relationships that determine organizational success.
The Alliance Management Landscape for Biotech CEOs
Biotech companies typically manage several distinct types of alliances, each with different delegation implications.
Co-development partnerships. Large pharma co-development deals are often the most complex and highest-stakes alliances a biotech will manage. These partnerships involve shared governance structures, joint steering committees, milestone and royalty economics, and co-decision authority over clinical development. The CEO’s personal involvement is highest here.
Technology licensing agreements. Technology in-licenses, platform partnerships, and research tool agreements involve contractual relationships that require consistent management but may have more limited CEO involvement once the agreement is in place.
CRO and CMO partnerships. Contract research and manufacturing organizations are operational partners rather than strategic partners in most cases. Managing these relationships requires operational discipline and contract management, but typically less CEO engagement.
Academic and institutional partnerships. Research collaborations with academic institutions require relationship management with principal investigators and technology transfer offices, as well as coordination of intellectual property, publications, and milestone progress.
Commercial partnerships. Co-promotion agreements, distribution partnerships, and commercialization alliances require active management as the company approaches and achieves commercialization milestones.
The CEO’s Non-Delegable Alliance Roles
In strategic partnerships, the CEO’s personal involvement is most valuable in four situations.
Alliance formation and negotiation. Major partnership formation, including term sheet negotiation, due diligence engagement, and term agreement, requires CEO involvement. These decisions shape the organization’s strategic direction and economic structure for years.
Senior partner executive relationships. The CEO should maintain personal relationships with counterpart C-suite executives at strategic partners. These relationships provide early warning of partner priorities and concerns, facilitate resolution of significant alliance issues, and strengthen the trust that makes complex co-development relationships work.
Joint steering committee leadership. For major co-development alliances, the CEO may serve on the joint steering committee or executive governance body. This forum shapes the most significant programmatic decisions in the partnership and requires CEO-level engagement.
Alliance crises and inflection points. When a significant alliance issue arises, such as a clinical hold on a jointly developed program, a disagreement about development strategy, or a partner reorganization that affects alliance leadership, the CEO must be personally engaged.
Delegating Alliance Operations
The day-to-day operational management of alliances should be owned by dedicated alliance management professionals.
Alliance management function. A vice president of alliance management, head of business development and alliances, or dedicated alliance managers should own the operational infrastructure of each partnership: maintaining the alliance governance calendar, preparing for joint committee meetings, tracking milestone progress, managing contractual obligations, monitoring the partner relationship, and identifying issues for escalation.
Joint committee preparation. For each joint governance meeting, alliance managers should prepare briefing materials, agenda proposals, data packages, and background analysis. The CEO participates in the meeting and contributes strategically; the alliance manager manages the preparation and follow-up logistics.
Contractual compliance and milestone tracking. Tracking contractual obligations, milestone targets, and payment schedules is an alliance management function. Alliance managers maintain the contractual compliance calendar and alert the CEO when significant milestones or obligations are approaching.
Partner communication at the working level. Day-to-day communication between the biotech and its partners on program-specific matters is managed by program teams, alliance managers, and functional leads. The CEO is not involved in routine partner communications.
For a broader framework on how pharma and biotech CEOs delegate strategically, see our resource on pharma CEO guide.
Building the Alliance Management Infrastructure
Effective delegation of alliance management requires organizational investment in the function.
A dedicated alliance management team. Organizations with multiple significant partnerships need dedicated alliance management professionals, not alliance management as a side responsibility for business development or legal staff. Investment in this function pays compounding returns in partnership quality and issue resolution speed.
Alliance governance calendar. A structured calendar of joint committee meetings, report submissions, milestone reviews, and contractual deadlines for each active alliance gives the alliance management team and the CEO a shared view of the alliance portfolio. Surprises in alliance management are usually failures of calendar management.
Alliance health monitoring. A systematic process for monitoring alliance health, including regular partner sentiment checks, formal alliance satisfaction assessments, and internal reviews of alliance performance, gives the CEO early warning of relationship deterioration before it reaches crisis level.
Documentation and knowledge management. Alliance agreements, governance records, committee meeting minutes, milestone documentation, and communication archives should be maintained in an accessible system that allows the CEO and alliance managers to access alliance history without requiring institutional memory from any single individual.
Managing Alliance Portfolio Risk
Biotech companies with multiple active alliances face portfolio-level risks: concentration of pipeline value in a single partner, conflicting obligations across partnerships, and management bandwidth constraints that limit the quality of alliance oversight across the portfolio.
The CEO should maintain a portfolio-level view of alliance risk, with alliance managers providing regular updates on the status and health of each alliance. When portfolio-level risks are identified, the CEO must make strategic decisions about resource allocation, priority setting, and potentially renegotiating or restructuring alliance terms.
This portfolio-level strategic role is distinctly CEO territory. The day-to-day operational management of individual alliances is alliance management territory.
Alliance Formation Strategy
Deciding which partnerships to pursue, which to pass on, and how to structure new alliances is a strategic function that requires CEO involvement.
The CEO should lead the organization’s alliance formation strategy: defining what capabilities and resources the biotech needs from external partnerships, setting criteria for partner selection, engaging with potential partners in early-stage exploratory conversations, and making final decisions on partnership pursuits.
Business development staff support alliance formation by identifying partnership opportunities, conducting due diligence, developing financial models, and preparing partnership analysis. Legal counsel manages the legal dimensions of negotiation. The CEO leads the strategic negotiation, with business development and legal providing support.
Cross-Functional Alliance Coordination
Successful alliance management requires coordination across the biotech’s internal functions: R&D, clinical development, regulatory affairs, manufacturing, and commercial teams all have obligations and touchpoints with external partners.
Alliance managers are responsible for coordinating across these internal functions to ensure that the biotech is meeting its alliance obligations and that partner-facing activities are coordinated and consistent. The CEO ensures that internal functions prioritize their alliance responsibilities appropriately and resolves resource conflicts when they arise.
According to McKinsey and Company, pharmaceutical and biotech companies with dedicated alliance management functions achieve significantly better partnership outcomes, including higher milestone completion rates and lower partner attrition rates, than those that manage alliances without dedicated resources.
Communicating Alliance Status to the Board
The board of directors has fiduciary interest in the health and performance of the company’s most significant alliances. Preparing and delivering board updates on alliance status is a CEO responsibility, but the preparation work can be substantially delegated.
Alliance managers and the CFO should prepare alliance status materials for board review: pipeline progress, milestone status, financial performance of the alliance economics, and any significant relationship or performance concerns. The CEO reviews these materials, adds strategic context, and presents to the board.
Succession Planning for Alliance Relationships
Alliance relationships are vulnerable to leadership transitions on both sides. When a key biotech executive who has been the primary partner-facing contact leaves the company, the alliance relationship is at risk.
Building alliance relationship resilience means ensuring that multiple executives have relationship investment with key partner contacts, that alliance governance structures are documented clearly enough to survive personnel changes, and that new leaders are introduced to key partners before the transition, not after.
Alliance managers should own the operational elements of this resilience: maintaining relationship maps, managing knowledge transfer during transitions, and facilitating introductions between new executives and partner counterparts.
The Financial Dimension of Alliance Management
Major biotech alliances involve significant financial flows: upfront payments, milestone payments, royalties, and in some cases cost-sharing arrangements. Managing these financial dimensions requires close coordination between alliance management and finance.
The CFO and finance team should own the financial management of alliance economics: tracking payment schedules, managing cost-sharing calculations, ensuring that revenue recognition is handled appropriately, and maintaining the financial models that project the value of each alliance. Alliance managers coordinate with finance to ensure that contractual financial obligations are tracked and met.
The CEO engages with alliance economics at the strategic level: evaluating the financial terms of new partnerships, assessing the financial implications of alliance milestones, and making decisions when financial issues in an alliance require renegotiation.
The Strategic CEO Presence in Alliances
The biotech CEO who has built effective alliance management delegation is available for the most strategically valuable alliance activities: senior partner executive conversations, joint governance leadership, alliance formation strategy, and crisis navigation. These are the activities that shape the organization’s most important external relationships and that cannot be provided by any staff member regardless of their expertise.
Protecting this strategic CEO role in alliances requires genuine organizational commitment to building and resourcing the alliance management function that handles everything else. The return on this investment, in partnership quality, milestone achievement, and relationship resilience, is one of the most direct and measurable returns on any delegation investment a biotech CEO can make.
For guidance on delegating the clinical operations dimensions of pharma and biotech partnerships, see our resource on pharma clinical ops.
Related Reading
For further context, explore Biotech CEO Delegation for Platform Technology Management and Automotive CEO Delegation for Aftermarket and Parts.